Picture of Cullinan Oncology logo

CGEM Cullinan Oncology Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Momentum

Relative Strength (%)
1m-5.6%
3m+60.05%
6m+44.78%
1yr+19.12%
Volume Change (%)
10d/3m+43.47%
Price vs... (%)
52w High-15.75%
50d MA+3.63%
200d MA+44.38%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-41.9%
Return on Equity-30.98%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Cullinan Oncology EPS forecast chart

Profile Summary

Cullinan Oncology, Inc. is a biopharmaceutical company. The Company is focused on creating standards of care for patients with cancer. The Company’s lead candidate, unpartnered program, CLN-619, is a monoclonal antibody designed to stabilize expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. The Company is evaluating CLN-978, is a CD19xCD3 T cell engager with extended serum half-life and, based on preclinical data, robust potency against target cells expressing low levels of CD19. The Company's Zipalertinib (CLN-081/TAS6417), is an orally available small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 (EGFRex20) insertion mutations with relative sparing of cells expressing wild-type EGFR. The Company’s other product candidates include CLN-049, CLN-418, and CLN-617.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
September 15th, 2016
Public Since
January 8th, 2021
No. of Shareholders
15
No. of Employees
85
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
43,065,645

CGEM Share Price Performance

Upcoming Events for CGEM

Q1 2024 Cullinan Oncology Inc Earnings Release

Cullinan Oncology Inc Annual Shareholders Meeting

Q2 2024 Cullinan Oncology Inc Earnings Release

Similar to CGEM

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ